Brief: Roche Receives FDA Clearance For Additional Alzheimer's Disease Cerebrospinal Fluid (Csf) Assays
27/06/2023 15:12
June 27 (Reuters) - Rogers Corp ROG.N :
* ROCHE RECEIVES FDA CLEARANCE FOR ADDITIONAL ALZHEIMER'S
DISEASE
CEREBROSPINAL FLUID (CSF) ASSAYS, SUPPORTING TIMELY DIAGNOSIS
AND TREATMENT DECISION-MAKING
Source text for Eikon: ID:nPn2dZxxZa
Further company coverage: ROG.N
Recent news on Rogers
See all newsRogers Corporation expected to post earnings of $1.19 a share - Earnings Preview
Brief: Rogers Corporation 2028 Revenue Target Is $1.05 Billion, +/- $50 Million
Rogers Corp reports results for the quarter ended June 30 - Earnings Summary
Rogers Q2 adjusted EPS misses analyst expectations despite high industrial, electronics demand
Rogers Corp expected to post earnings of 99 cents a share - Earnings Preview